Pharma: Other News To Note

• Bristol-Myers Squibb Co. and Pfizer Inc., both of New York, said the FDA extended the PDUFA date for their new drug application (NDA) for Eliquis (apixaban) by three months to June 28. The companies said they submitted additional information about the Eliquis clinical program to the FDA after filing the NDA, constituting a major amendment to the application.